You are here:

aflibercept (Zaltrap)

Advice

following a resubmission:

aflibercept (Zaltrap®) is accepted for use within NHS Scotland.

Indication under review: in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

In one randomised, double-blind, phase III study, aflibercept plus FOLFIRI chemotherapy regimen resulted in statistically significant longer overall survival compared with placebo plus FOLFIRI chemotherapy regimen.   However the effect was of relatively modest clinical benefit.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: aflibercept (Zaltrap)
SMC Drug ID: 878/13
Manufacturer: Sanofi-Aventis
Indication: In combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 10 March 2014

Archived Advice

Full submission 8 July 2013

Back